Specifically, PD-1/PD-L1 blocking antibodies lift TCR from obstructive PD-1 pathways, relieving T cells from exhaustion and reinvigorating T-cell responses at the tumor site [113,114,115]. This evidence concerns the gene PDCD1 and neoplasm.